The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1451
September 15, 2014
View Complete Issue         Table of Contents 2019 
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
September 15, 2014 (Issue: 1451)
The FDA has approved vorapaxar (Zontivity – Merck), an oral protease-activated receptor-1 (PAR-1) antagonist, for use with aspirin and/or clopidogrel to reduce the risk of thrombotic cardiovascular events in patients with peripheral arterial...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vorapaxar (Zontivity) for Prevention of Thrombotic Cardiovascular Events
Article code: 1451a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.